Peter Diamandis × Salim Ismail × Dave Blundin × Alexander Wissner-Gross

OpenAI’s October 6 release of 722 math solutions signals automation in verifiable research; cryptography’s absence drew Alex’s post-quantum risk warning.Meta’s active memory and 3.6 billion daily users offer reach, but Alex says Muse trails on cost.Alex forecasts the $1.8 billion virtual-cell initiative could yield cures for 5,000 diseases within two to three years, pending FDA acceptance.

Sarah Guo × Elad Gil × Greg Brockman

Brockman says AI is now creating reusable mathematical insight, with almost 400 important open problems solved through unexpected combinations of ideas.Drug development offers the clearest disruption case: a roughly 15-year, $1.5 billion process could accelerate in literature review, simulations, experiments, and regulatory writing, but biological data and long-term outcomes remain constraints.As code approaches near-zero cost, Brockman predicts cybersecurity spending should “far exceed software spending,” while OpenAI’s defender’s window and recurring model-led security testing remain catalysts to monitor.

Ian Quigley × Brandon Anderson × RJ Honicky

Leash’s reported edge is low-cost, carefully characterized data: its ten-person operation developed about 2,000 protein constructs and ran roughly 5,000 screens.On the hardest Kaggle split, none of roughly 2,000 teams beat chance, exposing how poorly models transfer to distant chemistry.Language agents now test hypotheses instantly against measured compounds, but coverage remains limited and potency calibration unfinished.

Pushmeet Kohli × Sal Candido × Brandon Anderson

AlphaFold 2 reproduced PDB-deposited structures, but ground state, dynamics, function, and design remain open, shifting the frontier toward richer biological context and raw cryo-EM data.Metagenomic sequences show useful scaling depends on statistical fit rather than volume, while calibrated pLDDT and clearer bottlenecks—not a 10x or 100x timetable—determine whether AI can safely accelerate drug development.

Patrick O'Shaughnessy × Andrew Huberman

Sleep is the near-term neurotechnology wedge because users already accept physiological measurement, while an eye mask reportedly measures REM, induces sleep-promoting eye movements, and amplifies REM, with related technology expected in roughly seven to 12 months.Huberman predicts Meta, OpenAI, Anthropic, and Elon’s Neuralink effort will converge on neural read/write biotech, but missing models of memory and thought, plus a possible 2027-28 downturn in optimization content, remain key risks.

Peter Diamandis × Salim Ismail × Dave Blundin × Alexander Wissner-Gross × Richard Socher

Recursive’s $670 million raise, backed by Google Ventures, Greycroft, Nvidia, and AMD, targets weak recursive improvement as AI-generated code increasingly enters system design.Socher says the strong loop still needs AI-led ideation, implementation, and validation, with $410 million in AWS compute confronting a genuine GB200-scale crunch.Sonnet 5.5’s reportedly 70% Terminal Bench 4.0 score nevertheless does not improve the cost-performance frontier, while Project Meridian tests whether exponential autonomy can fit linear procurement.

Graig Suvannavejh × Sam Fazeli × Eric Schmidt × Brian Skorney

Biotech’s 27% XBI gain through September masks a punishing ownership unwind, as underowned and heavily shorted names offset specialist-fund selling.Regeneron-Sanofi’s $1 billion upfront and AstraZeneca’s $2 billion Summit investment show strategic capital is flowing, but HARMONi-3 remains a potentially historic binary event.China-origin deals and Lilly’s obesity data sharpen competition, while financing, durability, tolerability, and endpoint risk still dictate outcomes.

Nathan Labenz × Prakash Narayanan × Jeremie Harris × Edouard Harris × Steve Hou × Joel Borgen × Daniel McKinnon

Trump-Xi contact could create an AI-crisis hotline, but without pre-vetted verification tools, an incident could trigger a demand to shut down a large cluster.Hyperscalers charge at least two to three times neo-cloud GPU prices; Gamo’s o3 loop found a 91-kilobase deletion, while Opus 5.5 scored about 50% on RareBench versus roughly 10% for LIRICAL.

Peter Diamandis × Salim Ismail × Dave Blundin × Alexander Wissner-Gross × Ben Lamm

Colossal is now worth over $10 billion with more than four spin-offs, while AI connects fragmented research and addresses 40–60% replication failure through standardized language.That data infrastructure may matter more than the model itself as comparative genomics spans thousands of genomes.Colossal has surpassed 300 edits at over 90% efficiency and is testing 1,000, with large-fragment DNA synthesis and a fully extrauterine mammalian birth within 24 months as catalysts amid ethical and regulatory constraints.

Daniel Ek

Spotify passed 700 million active users and 300 million premium subscribers; Daniel Ek became executive chairman January 1 and returned to building.Neko's $499 unit-economic-positive visit combines 53 blood markers, 6,000 images and clinician review in roughly an hour.Over 100,000 scans found serious, previously undiagnosed conditions in roughly 1% of members; population outcomes and budget effects remain unresolved.